Compare VTVT & EDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VTVT | EDF |
|---|---|---|
| Founded | 2015 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 143.7M | 160.5M |
| IPO Year | 2015 | 2010 |
| Metric | VTVT | EDF |
|---|---|---|
| Price | $42.70 | $4.90 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $53.00 | N/A |
| AVG Volume (30 Days) | 48.6K | ★ 235.9K |
| Earning Date | 05-14-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $14.00 | $4.14 |
| 52 Week High | $44.00 | $5.34 |
| Indicator | VTVT | EDF |
|---|---|---|
| Relative Strength Index (RSI) | 61.25 | 41.84 |
| Support Level | $31.93 | $4.83 |
| Resistance Level | $41.88 | $5.03 |
| Average True Range (ATR) | 3.13 | 0.10 |
| MACD | 0.48 | -0.02 |
| Stochastic Oscillator | 82.60 | 32.02 |
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin, currently in a Phase 3 trial, a potential novel first-in-class oral liver-selective glucokinase activator being investigated for the treatment of type 1 diabetes. The group and its development partners are investigating multiple molecules across different indications for chronic diseases. Its product pipeline are HPP737, Azeliragon, TTP-RA, TTP273, HPP971 / HPP3033, and HPP593.
Virtus Stone Harbor Emerging Markets Income Fund is a closed-end management investment company. Its investment objective is to maximize total return, which consists of income from its investments and capital appreciation. The Fund normally will invest at least 80% of its net assets (plus any borrowings for investment purposes) in emerging markets securities.